Clinical utility of botulinum toxin type A local injection therapy for head and forehead hyperhidrosis

J Dermatol. 2022 Jul;49(7):719-723. doi: 10.1111/1346-8138.16368. Epub 2022 Apr 7.


Head and forehead hyperhidrosis (HFH) is a disease that causes a large amount of sweating from the head region, and it significantly reduces patients' quality of life. Only a few reports have shown the effectiveness of botulinum toxin type A (BTX-A) local injection therapy (BTX-A therapy) for HFH. To clarify the benefits of BTX-A for HFH, BTX-A therapy was performed in 15 patients, and its efficacy was evaluated. The amount of sweating was measured by the ventilation capsule method and Minor's iodine-starch test. Evaluation was also performed using the Hyperhidrosis Disease Severity Scale (HDSS) and the Dermatology Life Quality Index (DLQI). In most cases, a remarkable antiperspirant effect was observed from 2 weeks after the injection, and the effect lasted for approximately 30 weeks. HDSS and DLQI improved along with the decrease in sweating. Two patients (13.3%) complained of transient mild ptosis. There were no serious side-effects. This study showed that BTX-A therapy is a safe and effective treatment for HFH.

Keywords: Dermatology Life Quality Index; Hyperhidrosis Disease Severity Scale; botulinum toxin type A; hyperhidrosis; sweating.

MeSH terms

  • Botulinum Toxins, Type A* / therapeutic use
  • Forehead
  • Humans
  • Hyperhidrosis* / drug therapy
  • Quality of Life
  • Sweating
  • Treatment Outcome


  • Botulinum Toxins, Type A